Regulatory News In Brief
This article was originally published in The Tan Sheet
Executive Summary
Caffeine claims for avitae cross the line; Essiac Tea in hot water with FDA; studies are claims for Nature’s Pearl supplement; “Statin Support” label makes CoQ10 a drug; more Regulatory News In Brief.
You may also be interested in...
Regulatory News In Brief
FDA fires warning shot on Breathable Foods’ “inhalable caffeine”; agency guidance advises against phthalate excipients in drugs; pandemic adverse event reporting guidance finalized; Globe All Wellness recall of tainted supplements is insufficient; more Regulatory News In Brief.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.